Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TMCI
Upturn stock ratingUpturn stock rating

Treace Medical Concepts Inc (TMCI)

Upturn stock ratingUpturn stock rating
$6.95
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TMCI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $8.35

1 Year Target Price $8.35

Analysts Price Target For last 52 week
$8.35 Target price
52w Low $4.54
Current$6.95
52w High $10.79

Analysis of Past Performance

Type Stock
Historic Profit -35.11%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 439.05M USD
Price to earnings Ratio -
1Y Target Price 8.35
Price to earnings Ratio -
1Y Target Price 8.35
Volume (30-day avg) 7
Beta 0.68
52 Weeks Range 4.54 - 10.79
Updated Date 08/15/2025
52 Weeks Range 4.54 - 10.79
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.79

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.29
Actual -0.28

Profitability

Profit Margin -23.01%
Operating Margin (TTM) -35.82%

Management Effectiveness

Return on Assets (TTM) -13.83%
Return on Equity (TTM) -46.89%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 439858225
Price to Sales(TTM) 2.05
Enterprise Value 439858225
Price to Sales(TTM) 2.05
Enterprise Value to Revenue 2.06
Enterprise Value to EBITDA -40.95
Shares Outstanding 63173100
Shares Floating 47366578
Shares Outstanding 63173100
Shares Floating 47366578
Percent Insiders 25.64
Percent Institutions 61.05

ai summary icon Upturn AI SWOT

Treace Medical Concepts Inc

stock logo

Company Overview

overview logo History and Background

Treace Medical Concepts, Inc. was founded in 2014. The company focuses on the surgical treatment of bunions and related deformities of the foot. They pioneered the Lapiplasty procedure.

business area logo Core Business Areas

  • Bunion Correction: Develops, manufactures, and markets the Lapiplasty System, a surgical procedure for correcting bunions.

leadership logo Leadership and Structure

John T. Treace is the CEO and founder. The company operates with a structure typical of a medical device company, with departments for R&D, manufacturing, sales, and marketing.

Top Products and Market Share

overview logo Key Offerings

  • Lapiplasty System: A patented surgical system for 3D bunion correction. Treace is estimated to have around 25% of the surgical bunion correction market. Competitors include Stryker (SYK), Wright Medical (now part of Stryker), and smaller players offering traditional osteotomy techniques. Revenue from this product accounts for the vast majority of Treace's total revenue.

Market Dynamics

industry overview logo Industry Overview

The orthopedic device market is experiencing growth, particularly in foot and ankle procedures. The market is driven by an aging population and increased demand for minimally invasive surgical options.

Positioning

Treace Medical Concepts is positioned as an innovator in the bunion correction space with its Lapiplasty system. Its competitive advantage lies in the patented technology and perceived benefits over traditional bunion surgeries, such as faster recovery times.

Total Addressable Market (TAM)

The estimated TAM for bunion correction procedures is around $5 billion. Treace is positioned to capture a significant portion of this TAM with increased adoption of Lapiplasty.

Upturn SWOT Analysis

Strengths

  • Patented Lapiplasty technology
  • Strong clinical data supporting Lapiplasty
  • Focus on a specific market segment (bunion correction)
  • Growing adoption among surgeons
  • Strong sales growth

Weaknesses

  • Reliance on a single product (Lapiplasty)
  • Relatively small company size
  • Requires surgeon training for Lapiplasty procedure
  • Limited brand recognition compared to larger orthopedic companies

Opportunities

  • Expand adoption of Lapiplasty into more markets
  • Develop new products for related foot and ankle conditions
  • Acquire complementary technologies or companies
  • Increase insurance coverage for Lapiplasty
  • Penetrate international markets

Threats

  • Competition from established orthopedic companies
  • Changes in reimbursement policies
  • Product liability lawsuits
  • Slower-than-expected adoption of Lapiplasty
  • Technological advancements by competitors

Competitors and Market Share

competitor logo Key Competitors

  • SYK
  • BSX
  • JNJ

Competitive Landscape

Treace's competitive advantage lies in its specialized focus on bunion correction and its patented Lapiplasty system. However, it faces competition from larger, more diversified orthopedic companies.

Growth Trajectory and Initiatives

Historical Growth: Treace has experienced rapid revenue growth in recent years, driven by increased adoption of Lapiplasty.

Future Projections: Analysts project continued revenue growth for Treace, although profitability may take several years to achieve.

Recent Initiatives: Treace has focused on expanding its sales force, increasing surgeon training programs, and publishing clinical studies supporting Lapiplasty.

Summary

Treace Medical Concepts shows good progress with their Lapiplasty system but must remain focused on sales growth and manage the competition of larger companies. Insurance coverage is important as well as international market penetration. Current losses are an ongoing concern. Positive clinical data can improve adoption.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Market Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Treace Medical Concepts Inc

Exchange NASDAQ
Headquaters Ponte Vedra, FL, United States
IPO Launch date 2021-04-23
Founder, Chairman & CEO Mr. John T. Treace
Sector Healthcare
Industry Medical Devices
Full time employees 477
Full time employees 477

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.